Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant

Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease

(2020) Waseem Amjad et al.   DIGESTIVE DISEASES AND SCIENCES

286. Hepatitis B Vaccine Compliance: Comparing 2-Dose and 3-Dose Vaccines

(2019) Katia Bruxvoort et al.   Open Forum Infectious Diseases

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

(2018) Randall Hyer et al.   VACCINE

Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States

(2018) Laurel Trantham et al.   VACCINE

Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant

(2018) Sarah Schillie et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS)

(2018) Danae Bixler et al.   CLINICAL INFECTIOUS DISEASES

Recent progress concerning CpG DNA and its use as a vaccine adjuvant

(2013) Hidekazu Shirota et al.   Expert Review of Vaccines

Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine

(2013) Renee Kim Kuan et al.   VACCINE

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

(2013) William L. Heyward et al.   VACCINE

Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants

(2013) Harm HogenEsch   Frontiers in Immunology

Immune Response of Hepatitis B Vaccine Among Persons With Diabetes: A systematic review of the literature

(2012) S. F. Schillie et al.   DIABETES CARE

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

(2012) Scott A. Halperin et al.   VACCINE

CpG DNA as a vaccine adjuvant

(2011) Christian Bode et al.   Expert Review of Vaccines